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ABSTRACT
Immunocytochemical detection of disseminated tumour
cells in the bone marrow of patients with primary breast
cancer at surgery has been shown to be an independent
prognostic factor in single institutional studies and in a
large pooled analysis. However, bone marrow sampling
and assessment of disseminated tumour cells is not a
routine procedure in the clinical management of patients
with breast cancer, but will certainly play a role in the
near future for risk stratification and monitoring of
therapeutic efficacy. Accurate identification of dissemi-
nated tumour cells in bone marrow must be based on
standardised methodologies and procedures. This review
describes these methodologies and the standardised
morphological criteria used for disseminated tumour cell
detection. The prognostic value of circulating tumour cells
detection in peripheral blood is demonstrated in patients
with metastatic disease but remains to be substantiated
at early stage. The significance of disseminated tumour
cells in bone marrow and in the blood for the prediction of
response to therapy is briefly summarised. Finally, this
review addresses the main biological questions raised by
disseminated tumour cells, in particular understanding
tumour dormancy and identifying metastatic stem cells.
In clinical practice, the most important prognostic
information about breast cancer is provided by
pathological staging, such as tumour grade,
tumour size, presence of lymphatic and vascular
invasion, axillary lymph node involvement and
steroid receptor status. Nonetheless, about 20–30%
of patients with a favourable prognosis relapse
within 5 years and many patients with poor
prognostic factors will survive for more than 10
years. In this context, there is a real need for new,
more accurate prognostic factors. One of the
promising new parameters is identification of the
presence of disseminated tumour cells (DTC) in
bone marrow (BM). DTC, the most precise term,
are also described by several synonyms such as
bone marrow micrometastasis or minimal residual
disease. The presence of BM DTC is clearly
associated with a poor outcome for patients with
stage I to III breast cancer.
1 The procedure is still
investigational according to the American Society
of Clinical Oncology 2007 update of recommenda-
tions for the use of tumour markers in breast
cancer,
2 and its incorporation into clinical manage-
ment algorithms is currently the focus of research.
Many different methodologies have been used to
detect DTC, but standardised guidelines have now
been published.
3 The current challenge for pathol-
ogists is to improve and standardise early detection
of DTC. In this review, we will summarise the
methodologies most commonly used to detect
DTC, discuss the clinical impact of DTC in bone
marrow at initial diagnosis and during follow-up
and treatment evaluation, and highlight the
biological and clinical questions raised by DTC.
METHODOLOGIES FOR DETECTION OF BONE
MARROW MICROMETASTASES
The methodology most commonly used to detect
DTC is immunocytochemistry performed on BM
aspirates. Immunocytochemistry currently
remains the gold standard for BM DTC detection,
with a sensitivity ranging from 1 DTC in 10
5 to 1
in 10
6 leucocytes.
Bone marrow aspiration
Ideally, this procedure should be performed under
general anaesthesia, at the time of initial surgery,
before the skin incision. If necessary, it can be
performed under local anaesthesia. Bone marrow
aspirates are usually performed from both anterior
iliac crests, as no difference has been reported
between anterior and posterior iliac crest aspira-
tions.
4 Bone marrow (5–10 ml) should be aspirated
and pooled in heparinised tubes, EDTA or sodium
citrate until further processing. Optimal storage
temperature is at 4–25uC. A Ficoll density gradient
centrifugation for tumour cell enrichment is
performed, ideally within the first 24 hours after
collection. A cell count is performed on the
interphase layer containing mononuclear cells,
and cytospins are prepared and smeared on
positively charged glass slides; 2–3610
6 cells per
patient are examined. The slides (3–6 slides per
patient) are air-dried at 4uC or at room tempera-
ture overnight before fixation
3 and immunostain-
ing.
Immunocytostaining
Antibodies
The majority of studies use the fact that breast
cancer is an epithelial cell tumour and that BM
normally does not contain any epithelial cells.
Various antibodies have been used over the years:
initially polyclonal antibodies raised against epithe-
lial membrane antigen (EMA), which was subse-
quently abandoned as this antibody can cross-react
with plasma cells and immature precursors in bone
marrow; then monoclonal antibodies raised against
various cytokeratins, mucins (MUC1), mammaglo-
bin and adhesion molecules such as EpCAM. The
most commonly used antibody at the present time
is A45/BB3 (Micromet, Munich, Germany), a
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several cytokeratins including CK8, CK18 and CK19. Other
antibodies include CK2 (mouse IgG1, Boehringer, Mannheim)
directed against CK18, and AE1/AE3 that reacts with basic and
acidic keratins covering a large spectrum of cytokeratins (CK10,
CK14–16, CK19 and CK1-8). The recommended revelation
system is the alkaline–anti-alkaline phosphatase technique with
levamisole as blocking agent. Cells are counterstained with
haematoxylin to visualise their nuclear morphology.
Quality control
Because haematopoietic cells can sometimes be stained by anti-
cytokeratin antibodies,
5 rigorous internal and external quality
control procedures must be applied.
Internal controls
Before the technique can be used in clinical practice, it should
first be evaluated on bone marrow samples from patients
without cancer (orthopaedic surgery specimens, for example) in
order to validate its specificity. The technique must also be
calibrated (primary antibodies and revelation system dilutions)
using breast cancer cell lines such as MCF7 or SKBR3 at
different dilutions, spiked into mononuclear cells from patients
without breast cancer. All specimens from breast cancer
patients must also be systematically examined in parallel with
controls, consisting of slides stained with isotype-matched
immunoglobulin.
External controls
Ring experiments are highly recommended to improve the
between-centre reproducibility of bone marrow analysis.
Analysis of cell preparations
Morphological analysis has been clearly shown to improve the
specificity of DTC identification and is highly recommended,
but optimal separation of DTC from cytokeratin-positive
haematopoietic or non-haematopoietic cells remains challen-
ging, as it is often difficult to detect single DTC in mononuclear
cell fractions from BM. Manual screening of 2–3610
6 cells and
2–3610
6 negative control cells using light microscopy is
performed by an experienced observer. Morphological analysis
of cytokeratin-positive cells is based on consensus criteria.
36The
read-out of positive cells should be controlled by at least two
independent observers. The screening of large volumes of
material by immunocytochemical techniques can be time-
consuming; automated image-analysis systems can be used. In
a European interlaboratory testing of well-known procedures
for immunocytochemical detection of epithelial cells in bone
marrow, the MDS1 from Applied Imaging screening sensitivity
was similar to manual screening, while ACIS from
Chromavision detected fewer cells.
7
Standardised interpretation according to European guide-
lines
367is required to improve the specificity of DTC detection.
c Samples are classified into two categories: positive or
negative.
– Positive samples are those with cytokeratin-positive cells
with disseminated tumour cell morphology. The number
of cells should be indicated.
– Negative samples are those with no positive immunocy-
tochemical stained cells or cytokeratin-positive cells with-
out disseminated tumour cell morphology (e.g.
haematopoietic cells, squamous cells).
c All cytokeratin-positive cells should be classified as dis-
seminated tumour cells, i.e. cytokeratin-positive cells with
disseminated tumour cell morphology or cytokeratin-posi-
tive cells.
The morphological features of DTC are:
c The presence of cell clusters (fig 1A).
c Large cell size with a clearly enlarged nuclear size and a high
nuclear-to-cytoplasmic ratio (fig 1B), and strong or irregular
cytoplasmic staining for cytokeratin.
c Cytokeratin filaments can be seen.
c Staining partially covers the nucleus. A large nucleolus can
be seen and the nucleus is often granular or stippled (fig 1B).
Some cytokeratin cells are clearly recognised as haematopoie-
tic or squamous cells (fig 1C).
According to morphological classification guidelines, positiv-
ity rates are about 13–15%,
58 in contrast with the 30–35%
positivity rates reported in studies based exclusively on
cytokeratin positivity without morphological analysis.
1
Notably molecular analysis of cytokeratin-positive BM cells
has shown that these cells may be malignant.
91 0 Clinical
studies
11 12 have also demonstrated the prognostic value of
cytokeratin-positive BM cells not classified as DTC and
cytokeratin-positive cells.
In order to increase the number of epithelial cells found in the
bone marrow, several workers have used immunomagnetic
methods of selection (IMS). Available techniques use antibodies,
linked to small paramagnetic beads or colloids of 1 nm
(ferrofluids), with an affinity for specific cells. The cells can
then be selected with a powerful magnet. Beads are available
linked to antiepithelial antibodies for positive selection, like
epithelial cell adhesion molecule (Ep-CAM), or linked to a
monoclonal antibody directed against CD45 for negative
selection of leucocytes.
13 The use of negative IMS increased
the frequency of positive BM in a large series from Norway but
did not improve the prognostic value of this detection.
14
Some studies have assessed DTC detection by using
molecular biology techniques such as real-time quantitative
PCR determination with several markers: CK19, MUC1,
15
urokinase-type plasminogen activator receptor (uPAR),
EpCAM
16 and mammaglobin.
17 This detection should be more
sensitive (1 tumour cell in 10
7 mononuclear cells) and more
effective. However, using PCR to detect DTC raises two
problems: firstly, the real problem of identifying appropriate
sensitive and specific markers; and secondly, a problem of
quantification. As no specific markers are available to detect
DTC in BM, it is therefore not recommended to detect DTC in
clinical trials by RT PCR alone without associated immunocy-
tochemical detection.
Prospects
DTC detection using more specific markers should improve the
clinical relevance and reproducibility of this new parameter.
One possibility would be to use markers that characterise each
subtype of breast carcinoma, such as HER2, as this status is
generally maintained in early metastasis such as DTC.
91 8EGFR
overexpression could also be promising in the basal-like
subgroup.
CLINICAL SIGNIFICANCE OF DTC
Several studies over the last two decades have assessed the
prevalence and prognostic value of micrometastatic dissemina-
tion of breast cancer cells in bone marrow. These studies
estimated that 12–45% of patients with primary operable breast
Review
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determined by immunocytochemistry.
1 5 12 19–22 Table 1 sum-
marises the major studies using immunocytochemical detection
of DTC in BM. In a pooled analysis of nine studies comprising
4703 patients with stage I, II or III breast cancer, the presence of
micrometastases at diagnosis was detected in 30.6% of patients.
With a follow-up of 10 years, this analysis demonstrated that
DTC in BM at the time of the initial diagnosis of breast cancer
was a significant and independent prognostic factor with
respect to poor overall survival and breast cancer-specific
survival (univariate mortality ratios: 2.15 and 2.44, respectively;
p,0.001 for both outcomes) and poor disease-free survival and
distant disease-free survival during the 10-year observation
period (incidence rate ratios: 2.13 and 2.33, respectively;
p,0.001 for both outcomes). This evidence could be sufficient
to include DTC analysis in the routine staging of primary breast
cancer. However, technical issues remain controversial and bone
marrow aspiration is not considered to be a convenient
procedure for patients.
Peripheral blood would be an ideal source for the detection of
tumoural cells, and sequential peripheral blood analyses are
more acceptable. Depending on the detection technique used,
circulating tumoural cells (CTC) were revealed in 50–100% of
patients with metastatic breast cancer.
23 Even in patients with
no clinical signs of overt metastases, however, detection rates
range from 10% to 60%.
24 Detection of CTC with the CellSearch
system (Veridex, Warren, New Jersey, USA), which detects
CTC using Ep-CAM coated beads for enrichment followed pan
CK staining, provided significant prognostic information before
and also early (4 weeks) after initiation of chemotherapy in
patients with metastatic breast cancer.
25 CTC had superior and
independent prognostic value of tumour burden and disease
phenotype.
26 In contrast to patients with metastatic disease,
and despite promising results,
27 the prognostic relevance of CTC
in the blood of patients with early-stage disease without overt
metastasis needs to be demonstrated in prospective multicenter
studies.
28
It is not clear if CTC measurements could replace the
examination of bone marrow. Two immunocytochemical
studies demonstrated statistically significant correlations
between DTC detection in BM and CTC in blood, but BM
was more frequently positive than blood.
29 30 Recently, Benoy et
al found that real-time RT-PCR based detection of DTC in BM
had superior significance to CTC measurements in blood.
31 In
addition, Wiedswang et al, with an ICC assay, showed that BM
but not blood analyses provided prognostic information.
32 These
finding do not support an exchange of DTC in BM with CTC
from blood.
An important potential application for DTC detection is the
monitoring of therapeutic efficacy in the adjuvant setting which
can currently only be assessed retrospectively in large-scale
clinical trials after an observation period of at least 5 years.
Persistence of DTC in BM some years after diagnosis and initial
therapy is still an indicator of subsequent systemic treatment
failure.
33–35 Persistence or disappearance of DTC after systemic
treatment could therefore be used as a surrogate marker of
treatment response.
36 Studies have shown that adjuvant
chemotherapy has no effect on the elimination of single
dormant tumour cells in the BM of high-risk breast cancer
patients.
37 38 This emphasises the need to develop therapeutic
agents that are active on non-proliferating cells.
Bisphosphonates have been used to eliminate tumour cells in
BM persisting after adjuvant therapy. The most promising
agents are antibodies such as edrecolomab directed against
EpCAM
39 or trastuzumab directed against HER2.
40 Large-scale
prospective clinical trials must now be conducted to determine
whether eradication of DTC in BM after systemic therapy
results in longer survival.
BIOLOGICAL AND CLINICAL QUESTIONS RAISED BY
MICROMETASTATIC CELLS
The micrometastasis phenomenon is usually described as
‘‘tumour cell dormancy’’,
41 added as a late step of the metastatic
cascade.
42 Although dormancy regulation is a key element of
micrometastasis biology, micrometastatic cells can be assumed
to be more than just dormant cancer cells; they could help us to
understand certain aspects of metastasis biology. The main
clinical and biological questions raised by the micrometastatic
process and the current answers to these questions, are
described below.
How and when does micrometastasis occur?
The main clinical study reported that cytokeratin or mucin
positive BM cells are associated with tumour size, grade,
negative hormone receptors and lymph node metastases.
1
Using a more stringent detection technique, we did not
reproduce any of these results,
8 although they have been
confirmed by others.
43 This might suggest that micrometastatic
dissemination occurs in highly proliferative tumours, when a
critical tumour size has been reached. However, DTC may be
found at earlier stages of primary tumour development, and
comparative genomic hybridisation analyses of disseminated
Figure 1 Examples of A45/BB3-positive disseminated tumour cells (DTC) and haematopoietic cells. (A) Clusters of DTC. (B) Isolated DTC. The cell is
taller than other surrounding cells, with a high nuclear/cytoplasmic ratio; it shows strong and irregular cytoplasmic staining for cytokeratin.
(C) Haematopoietic cell.
Review
572 J Clin Pathol 2008;61:570–576. doi:10.1136/jcp.2007.046649cancer cells were in favour of early dissemination of breast
cancer cells to the BM.
10 44 Supervised transcriptomic profiling
of 19 primary tumours has been reported,
45 but this micro-
metastasis-associated profile has not been further validated by
independent unsupervised analysis. No pathological studies
have demonstrated a link between micrometastasis detection
and the recently described breast cancer subtypes.
46 Therefore,
although BM DTC may appear early, it is unknown whether
they correspond to a genetically homogeneous subgroup of
primary cancers.
Among the mechanisms of breast cancer cell dissemination to
the BM, bone and bone marrow homing of cancer cells may
depend on similar molecular determinants, especially the SDF1/
CXCR4 axis.
47 48 CXCR4 is a G protein-coupled receptor,
49 which
plays a role in the chemotaxis of breast cancer cells. This cellular
response is attributed to activation of the PI3K/PTEN/AKT/
mTOR signalling pathway,
49 rather than the MAP/ERK path-
way.
50 51 CXCR4 expression in 142 primary breast cancers has
been shown to be associated with the detection of BM DTC.
52
This pathway might be responsible for early dissemination of
breast cancers, as circulating cancer cells detected in the blood are
also characterised by activation of PI3K.
53 Epithelial-mesenchy-
mal transition and primary tumour microvessel density may also
be involved in the onset of DTC.
54 55 Finally, the molecular
determinants responsible for the establishment of BM DTC are
not clearly understood at the present time. BM DTC could be a
useful tool to assess the efficiency of the entire cancer cell
migration process and should be analysed together with
circulating tumour cells in blood and primary breast tumours.
Are micrometastatic cells metastatic progenitors?
Bone marrow is the host organ of breast cancer metastases,
which is the most accessible tissue for analysis, as liquid
aspirates can be performed under local anaesthesia or during
primary surgery. It is of critical importance to determine
whether DTC are (or are not) the metastatic progenitors of
bone and/or distant non-bone metastasis. A negative answer
would limit the accuracy of bone marrow DTC as a biological
model, a target for adjuvant treatment and a marker of
response. Paget
56 was the first to describe the non-random
growth of metastases, and the sustaining molecular determi-
nants of cancer cell homing have been recently charac-
terised.
52 57 58 If BM DTC are derived from the specific spread
of a few tumour subclones into flat bones, their ability to
recirculate to other organs would be somehow limited.
Consequently, their detection would be linked to an increase
of bone metastasis at primary relapse in patients, but not to
that of other metastatic sites. Micrometastases retained their
clonogenic and tumourigenic capacities in many biological
reports.
59–61 Clinical studies have reported a link between BM
DTC and the onset of bone metastasis,
184 3strongly supporting
the idea of local growth of DTC into macrometastases.
Table 1 Major clinical studies of the prognostic value of disseminated tumour cells (DTC) detection in bone marrow (BM) by immunocytochemistry
and prognostic value on disease and overall survival (univariate and multivariate analysis)
Reference Sampling Marker No. patients
Detection
rate (%)
Follow-up
(mth)
Disease free survival Overall survival
Univ Multiv Univ Multiv
Redding 1983
79 Smear MUC 110 28 NA NA NA NA
Manegold 1988
80 Biopsy CK/PKK1 50 8 NA NA NA NA
Smear
Landys 1998
81 Biopsy CK/AE1–AE3, KL1, CAM 5-2 128 19 240 NA NA Yes NA
Salvadori 1990
82 Biopsy CK/MBr1 121 16.5 48 No No NA NA
Mathieu 1990
83 Biopsy MUC/EMA, HMFG2 93 1 No No No No
CK/KL1, AE1–AE3, CAM5-2
Kirk 1990
84 Smear MUC/anti-milk fat globulin
LICR.LON.M8.4
25 48 34 No NA NA NA
Singletary 1991
85 Smear CK/AE1, AE3, MAK-6 71 38 11 No No No No
MUC/113F1, 260F9, 317G5
Cote 1991
86 Smear MUC/C26, T16 49 36.7 30 Yes Yes NA Na
CK/AE-1
Schlimok 1992
87 Cytospin CK18/CK2 187 18 39 Yes Yes NA NA
Harbeck 1994
88 Smear CK 100 38 34 Yes Yes No Yes
MUC/EMA
Me ´nard 1994
89 Cytospin CK/MBr1, MBr8, CK18/CK2,
MUC1
197 31 NA NA NA NA NA
Molino 1997
90 Cytospin CK/MBr1, MBr8, MOV8, MOV16
MluC1
109 31 36 No No No No
Funke 1996
91 Cytospin CK18/CK2 234 38 NA NA NA NA NA
Diel 1996
92 93 Smear MUC/TAG12 (2E11) 727 43.3 78 Yes Yes Yes Yes
Mansi 1999
12 94 Smear EMA 350 25.4 150 Yes No Yes No
Lyda 2000
95 Biopsy CK/AE1–AE3, 35bH11 CAM 5-2 54 31 38 Yes NA NA NA
Untch 1999
96 Cytospin CK18/CK2 581 28 No No No No
Braun 2000
11 Cytospin CK/CK8,18,19 (A45 B/B3) 552 36 36 Yes Yes Yes Yes
Gerber 2001
20 Cytospin CK/CK8,18,19 (5D3) 554 37 54 Yes Yes Yes Yes
Gebauer2001
21 Smear CK, MUC/EMA 396 42 75 Yes Yes Yes Yes
Kasimir-Bauer 2001
97 Cytospin CK/CK8,18,19 (A45 B/B3) 128 34 24 NA NA NA NA
Naume 2004
5 Cytospin CK/AE1/AE3 819 13 49 Yes Yes Yes Yes
Braun 2005
1 Various Various 4703 30.6 63 Yes Yes Yes Yes
Bidard 2007
8 Cytospin CK/CK8,18,19 (A45 B/B3) 621 15 50 Yes Yes Yes Yes
CK, cytokeratin; Muc, mucin; EMA, epithelial membrane antigen; NA, not available.
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be a favourite site of breast cancer relapse.
84 3 However, the
CXCR4 receptor is reported to be involved in homing to both
sites,
52 but the current literature does not provide strong
evidence for a common pool of genes responsible for coupled
homing to bone marrow (or flat bones) and liver. The other
alternative is that bone marrow may act as a long-term reservoir
of tumour cells, which can recirculate to other distant organs
before growing into metastases.
62 The high genetic heterogene-
ity
63 of BM micrometastatic cells might be responsible for
recirculation of some cancer seeds from the bone marrow to
different host organs. However, no biological or clinical study
has directly reported such a process for BM DTC and there is
currently no direct evidence suggesting that they are responsible
for the late growth of lung of liver metastases. On the contrary,
many biological models have reported that the micrometastatic
dissemination of mammary tumours occurs in most of the
target organs of metastases
64–66 and is not restricted to a unique
reservoir in the bone marrow. Also, 40 months after the surgical
treatment of non-metastatic breast cancer, the detection of
circulating cancer cells in the peripheral blood was not
correlated with the presence of bone marrow DTC.
32 Finally,
the local growth of some BM DTC into bone macrometastasis is
clinically and biologically rational. In the case of distant non-
bone or local relapses predicted by BM DTC,
8 these cells mostly
appear as a marker of a body-wide dissemination of invasive
cancer cells rather than the body’s only long-term reservoir of
disseminated cancer cells.
How is micrometastatic dormancy regulated?
Dormancy may be induced in disseminated cancer cells by lack
of the primary tumour microenvironment (absence of stimulat-
ing growth factors,
67 presence of growth-inhibiting cytokine
68).
Metastatic growth may be a rare and stochastic event secondary
to selection and mutations of dormant cancer cells.
69 The end of
dormancy may also be induced by any change of the
microenvironmental homoeostasis, such as the presence of
growth factors or an immune response.
70 Many groups
investigating the mechanisms of dormancy have reported the
role of integrin a5 b1 in regulating breast cancer cell dormancy.
This integrin is activated by the urokinase-type plasminogen
activator receptor (uPAR). Its main signalling pathway is the
FAK/Src and ERK pathway to promote cell mobility; inhibition
of this integrin leads to cancer cell dormancy in biological
models.
71 72 Integrin a5 b1 appears to be necessary, via the PI3K/
AKT pathway, for the survival of dormant cancer cells.
68 uPAR
expression by BM DTC has also been linked to a poorer
prognosis in a population of micrometastatic patients.
16
Regulation of cancer cell dormancy may also involve genes
and other processes, which regulate primary tumour growth.
Finally, most BM DTC-positive patients never relapse, while
others experience dramatic metastatic progression. These
different outcomes cannot be explained at the present time
and require further investigation.
Micrometastasis and cancer stem cells
The role of cancer stem cells in the establishment of metastasis
remains controversial in many theoretical proposals and
reviews.
73–76 Experimentally, CD44+/CD242/low cancer cells, a
phenotypeassociatedwitha stemcellpattern,exhibitaninvasive
phenotype,
77 78 which is a prerequisite to metastasis. In a report
on 50 cases, most BM micrometastatic breast cancer cells
exhibited a stem cell-like immunohistochemical phenotype.
76
CONCLUSION
BM DTC detection is a very promising prognostic parameter
that will improve clinical management of patients with breast
cancer in the near future. DTC detection must now be
implemented in clinical trials to improve treatment selection.
DTC specificity is considerably increased by histological
examination according to international guidelines and must be
submitted to high-level quality control. The future development
of targeted therapies against BM DTC should significantly
improve patient outcome and raises interesting new biological
questions that should further our understanding of breast
cancer carcinogenesis.
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